Experiences with helicobacter pylori treatment in Iran

Iranian Journal of Medical Sciences

Volumn 31, Issue 4, 2006, Pages 181-185

  Saberi Firoozi, Mehdi ^a   Nejabat, M ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Eradication; H. Pylori; Iran; Treatment experiences

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BISMUTH CITRATE; CIPROFLOXACIN; CLARITHROMYCIN; FAMOTIDINE; FURAZOLIDONE; HISTAMINE H2 RECEPTOR ANTAGONIST; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; RIFABUTIN; TETRACYCLINE;

ABDOMINAL PAIN; ANOREXIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIZZINESS; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG POTENTIATION; ERADICATION THERAPY; FATIGUE; FEVER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IRAN; MONOTHERAPY; NAUSEA AND VOMITING; REVIEW; TREATMENT DURATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

EID: 33845463757     PISSN: 02530716     EISSN: 17353688     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Reed PI, Johnston BJ. Treatment of helicobacter pylori infection. Biomed Pharmacother 1997; 51: 13-21.
2. Correa P. Is gastric carcinoma an infection disease? N Engl J Med 1991; 325: 1170-1.
3. Massarrat S, Saberifiroozi M, Soleimani A, et al. Peptic ulcer disease, irritable bowel syndrome and constipation in two populations in Iran. Eur J Gastroenterol Hepatol 1995; 7: 427-43.
4. Vakil N. Primary and secondary treatment for Helicobacter pylori in the United States. Rev Gastroenterol Disord 2005; 5: 67-72.
5. Malfertheiner P, Megraud, O'morain C, et al. Current concepts in the management of Helicobacter pylori infection. The Maastricht 2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
6. Mcloughlin RM, O'morain CA, O'Connor HJ. Eradication of Helicobacter pylori: recent advances in treatment. Fundam Clin Pharmacol 2005; 19: 421-7.
7. Malekzadeh R, Mohamadnejad M, Siavoshi F, Massarrat S. Treatment of Helicobacter Pylori infection in Iran: Low Efficacy of Recommended Western Regimens. Arch Iranian Med 2004; 7: 1-8.
8. Zendehdel N, Nasseri-Moghaddam S, Malekzadeh R, et al. Helicobacter pylori reinfection rate 3 years after successful eradication. J Gastroenterol Hepatol 2005; 20: 401-4.
9. Gunaid AA, Hassan NA, Murray-Lyon IM. Recurrence of Helicobacter pylori infection 1 year after successful treatment: Prospective cohort study in the Republic of Yemen. Eur J Gastroenterol Hepatol 2004; 16: 1309-14.
10. Graham DY, Operkun AR, Klein PD. Clarithromycin for the eradication of Helicobacter pylori. J Clin Gastroenterol 1993; 16: 292-4.
11. Peterson WL, Graham DY, Marshal B, et al. Clarithromycin as mono therapy for eradication of Helicobacter pylori: a randomized double-blind trial. Am J Gastroenterol 1993; 88: 1860-4.
12. Saberi Firoozi M, Massarrat S, Zare S, et al. Effect of triple therapy or amoxicillin plus omeprazole or amoxicillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized, controlled study. Am J Gastroenterol 1995; 90: 1419-23.
13. Bayerdorffer E, Mannes GA, Sommer A. High dose omeprazole treatment combined with amoxicillin eradicates H. pylori. Eur J Gastroentrol Hepatol 1992; 4: 697-702.
14. Alizadeh-Naeeni M, Saberi-firoozi M, Pourkhajeh A, et al. Effect of Helicobacter pylori eradication or of ranitidine plus metoclopramide on Helicobacter pylori positive functional dyspepsia: a randomized, controlled follow up study. Digestion 2002; 66: 92-8.
15. Mousavi S, Toussy J, Yaghmaie S, Zahmatkesh M. Azithromycin in one week quadruple therapy for H. pylori eradication in Iran. World J Gastroentrol 2006; 12: 4553-6.
16. Amini M, khedmat H, Yari F. Eradication rate of helicobacter pylori in dyspeptic patients. Med Sci Monit 2005; 11: CR193-5.
17. Siavoshi F, Pourkhajeh AH, Merat Sh, et al. Susceptibility of various strains of Helicobacter pylori to selected agents. Arch Intern Med 2000; 3: 60-3.
18. Teo EK, Fock KM, Ng TM, et al. Metronidazole-resistance Helicobacter pylori in an urban Asian population. J Gastroenterol Hepatol 2000;15: 494-7.
19. Malekzadeh R, Merat Sh, Derakhshan MH, et al. Low Helicobacter pylori eradication rate with 4-and 7-day regimens in an Iranian population. J Gastroenterol Hepatol 2003; 18: 13-7.
20. Roghani HS, Massarrat S, Pahlewanzadeh MR, Dashti A. Effect of two different doses of metronidazole and tetracycline in bismuth triple therapy on eradication of Helicobacter pylori and its resistant strains. Eur J Gastroenterol Hepatol 1999; 11: 709-12.
21. Fakheri H, Malekzadeh R, Merat S, et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther 2001; 15: 411-6.
22. Sotoudehmanesh R, Malekzadeh R, Vahedi H, et al. Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidozle based regimen. Digestion 2001; 64: 222-5.
23. Ebrahimi-Dariani N, Mirmomen S, Mansour-Ghanaei F, et al. The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy. Med Sci Monit 2003; 9: PI105-8.
24. Bahremand S, Nematollahi LR, Fourutan H, et al. Evaluation of triple and quadruple Hlicobacter Pylori eradication therapies in Iranian children: A randomized clinical trial. Eur J Gastroenterol Hepatol 2006; 18: 511-4.
25. Vakil N. Helicobacter pylori Treatment: a practical Approach. Am J Gastroenterol 2006; 101: 497-9.
26. Saad RJ, Schoenfeld P, Kim HM, et al. Levofloxacin-based triple therapy versus Bismuth-based quadruple therapy for persistent Helicobacter pylori Infection: a Meta-analysis. Am J Gastroenterol 2006; 101: 488-9.